A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

Provided is a method for accurately measuring coagulation time of blood samples showing various coagulation reactions. The method for measuring blood coagulation time includes measuring coagulation reaction of a sample prepared by mixing a subject specimen and a coagulation time measurement reagent; calculating weighted average time of a calculation target area of a waveform related to coagulation velocity from the resulting measurement data; and determining the weighted average time as blood coagulation time.

Disclosed are novel D-dimer specific aptamers and methods of their use.

The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the initial fibrinogen concentration in a biological sample, to the use of fibrinogen added to a biological sample in at least one predetermined concentration, to a device for determining the initial fibrinogen concentration in a biological sample, to a computer program comprising program code means for causing a computer to carry out at least several steps of the method according to the invention, to a computer readable non-transitory storage medium containing instructions for carrying out at least some steps of the method according to the invention, and to a kit for determining the initial fibrinogen concentration in a biological sample.

A method to make it possible to obtain a value related to the amount of DD by FDP measurement. The method includes optically measuring a first calibration sample prepared from an FDP measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of fibrin/fibrinogen degradation product FDP to the content of DD, acquiring first calculation data based on temporal change of optical information obtained by optical measurement of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value related to the ratio of the content of FDP to the content of DD, acquiring second calculated data based on a temporal change in optical information obtained by optical measurement of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD based on the first calculation data, the second calculation data, the first value, and the second value.

The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.

The present invention relates to device for determining a fibrinogen level in a sample comprising, a first input for obtaining an attenuance signal over time indicative of a fibrin polymerization of said sample, a second input for obtaining a reactant concentration signal over time indicative of a reactant concentration in said sample, wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit running a model using the reactant concentration signal as an input to provide a simulated attenuance signal over time, and an evaluation unit configured to infer the fibrinogen level of said sample by comparing the attenuance signal over time with the simulated attenuance signal over time.

A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.

The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed.

The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient. The method preferably includes a step that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.